The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Open accessAbstract
BACKGROUND: The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects. METHODS: In a double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI and were receiving guideline-recommended therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel. The primary efficacy end point was a composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization; the key secondary end point was stent thrombosis at 48 hours. The primary safety end point was severe bleeding at 48 hours. RESULTS: The rate of the primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (adjusted odds ratio with cangrelor, 0.78; 95% confidence interval [CI], 0.66 to 0.93; P=0.005). The rate of the primary safety end point was 0.16% in the cangrelor group and 0.11% in the clopidogrel group (odds ratio, 1.50; 95% CI, 0.53 to 4.22; P=0.44). Stent thrombosis developed in 0.8% of the patients in the cangrelor group and in 1.4% in the clopidogrel group (odds ratio, 0.62; 95% CI, 0.43 to 0.90; P=0.01). The rates of adverse events related to the study treatment were low in both groups, though transient dyspnea occurred significantly more frequently with cangrelor than with clopidogrel (1.2% vs. 0.3%). The benefit from cangrelor with respect to the primary end point was consistent across multiple prespecified subgroups. CONCLUSIONS: Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding. (Funded by the Medicines Company; CHAMPION PHOENIX ClinicalTrials.gov number, NCT01156571.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease
De Bruyne, B., Pijls, N. H. J., Kalesan, B., Barbato, E., Tonino, P. A. L., Piroth, Z., Jagic, N., Möbius-Winkler, S., Rioufol, G., Witt, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205361 · Cited by 2,772
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,308
Self-citationMehta, S. R., Cannon, C. P., Fox, K. A. A., Wallentin, L., Boden, W. E., Spacek, R., Widimsky, P., McCullough, P. A., Hunt, D., Braunwald, E., et al. (2005) · JAMA · doi:10.1001/jama.293.23.2908 · Cited by 827
Mehta, S. R., Tanguay, J.-F., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H.-J., Budaj, A., Avezum, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 825
Self-citationDose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909475 · Cited by 768
Intravenous Platelet Blockade with Cangrelor during PCI
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., Kleiman, N. S., Goodman, S. G., White, H. D., Mahaffey, K. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908629 · Cited by 648
Self-citationPlatelet Inhibition with Cangrelor in Patients Undergoing PCI
Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., Pollack, C. V., Montalescot, G., Mahaffey, K. W., Kleiman, N. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908628 · Cited by 625
Self-citation
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Self-citation2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,558
Reed, G. W., Rossi, J. E., & Cannon, C. P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30677-8 · Cited by 1,507
Anderson, J. L., & Morrow, D. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1606915 · Cited by 1,115
Horlocker, T. T., Vandermeuelen, E., Kopp, S. L., Gogarten, W., Leffert, L. R., & Benzon, H. T. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000763 · Cited by 932
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001038 · Cited by 829
Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction
Montalescot, G., van 't Hof, A. W., Lapostolle, F., Silvain, J., Lassen, J. F., Bolognese, L., Cantor, W. J., Cequier, Á., Chettibi, M., Goodman, S. G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407024 · Cited by 661
Self-citationPretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
Montalescot, G., Bolognese, L., Dudek, D., Goldstein, P., Hamm, C., Tanguay, J.-F., ten Berg, J. M., Miller, D. L., Costigan, T. M., Goedicke, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1308075 · Cited by 657
Self-citationRao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Adaptive Designs for Clinical Trials
Bhatt, D. L., & Mehta, C. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510061 · Cited by 499
Self-citationIbánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0243 · Cited by 458
Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02391-6 · Cited by 445
2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0224 · Cited by 418
Self-citationInternational Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., Sibbing, D., So, D. Y. F., Trenk, D., Alexopoulos, D., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031164 · Cited by 397
Self-citationNarouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Novel antiplatelet agents in acute coronary syndrome
Franchi, F., & Angiolillo, D. J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.156 · Cited by 353
Self-citationSteg, P. G., Bhatt, D. L., Hamm, C. W., Stone, G. W., Gibson, C. M., Mahaffey, K. W., Leonardi, S., Liu, T., Skerjanec, S., Day, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61615-3 · Cited by 346
Self-citation2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m09_01 · Cited by 328
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Angiolillo, D. J., Bhatt, D. L., Cannon, C. P., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Granger, C. B., Holmes, D. R., Lopes, R. D., Mehran, R., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050438 · Cited by 302
Self-citationBivalirudin versus Heparin Monotherapy in Myocardial Infarction
Erlinge, D., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., Hamid, M., Swahn, E., Henareh, L., Wagner, H., Hårdhammar, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706443 · Cited by 301
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
Self-citationCurrent and future antiplatelet therapies: emphasis on preserving haemostasis
McFadyen, J. D., Schaff, M., & Peter, K. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.206 · Cited by 281
The Primary Outcome Fails — What Next?
Pocock, S. J., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510064 · Cited by 274
Self-citationCarbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Alternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Deliargyris, E. N., Mahaffey, K. W., et al. (2016) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.116.003612 · Cited by 12
Self-citation
Metadata
- Authors
- Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Price, M. J., Leonardi, S., Gallup, D., Bramucci, E., Radke, P. W., Widimský, P., Tousek, F., Tauth, J., Spriggs, D., McLaurin, B. T., Angiolillo, D. J., Généreux, P., Liu, T., Prats, J., Todd, M., Skerjanec, S., White, H. D., & Harrington, R. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-04-04
- Volume
- 368
- Issue
- 14
- Pages
- 1303-1313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2150655309
- Cited by
- 840
- References
- 29
- FWCI
- 69.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.